Dr. Dean Y. Li, president of Merck Research Laboratories, said in the release that the positive findings represented an important milestone in the collaboration with Moderna:
"Over the last six years, our teams have worked closely together combining our respective expertise in mRNA and immuno-oncology with a focus on improving outcomes for patients with cancer." Both Moderna and Merck will discuss results with regulatory authorities and initiate a Phase 3 study in melanoma next year while rapidly expanding to additional tumor types.
Moderna CEO Stéphane Bancel, said the partnership would also bring individualized cancer treatments to patients., as well as with health authorities," Bancel added. in October after Merck exercised its option to jointly develop and commercialize the treatment. The rates of melanoma have been rising over the past few decades, with nearly 325,000 new cases diagnosed worldwide in 2020. In the U.S., skin cancer is one of the most common types of cancer diagnosed, and melanoma accounts for a large majority of skin cancer deaths. It is estimated there will be nearly 100,000 new cases of melanoma diagnosed and almost 8,000 deaths resulting from the disease in the U.S. in 2022.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: fox13seattle - 🏆 328. / 59 Read more »
Source: FOX29philly - 🏆 570. / 51 Read more »